Last update 09 Nov 2024

Simmitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
希美替尼, SOMCL 15 290, SOMCL-15-290
+ [1]
Target
FGFRs x M-CSF x VEGFR2
Mechanism
FGFRs antagonists(Fibroblast growth factor receptors antagonists), M-CSF inhibitors(Macrophage Colony Stimulating Factor 1 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases+ [3]
Active Indication
Metastatic Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaBile Duct Neoplasms+ [12]
Inactive Indication
Transitional Cell Carcinoma
Originator Organization
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
Active Organization
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of SciShanghai Runshi Pharmaceutical Technology Co., Ltd.CSPC Pharmaceutical Group Ltd.CSPC Pharmaceutical Group Ltd.
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

12
Clinical Trials associated with Simmitinib
NCT06656091 / Not yet recruitingPhase 3
Simmitinib Versus Investigator's Choice of Chemotherapy for Participants With Advanced or Metastatic Oesophageal Squamous Cell Carcinoma : a Randomised, Open-label, Multicentre, Phase 3 Study
ChiCTR2400089300 / SuspendedPhase 1IIT
An open-label and multicenter Phase ? Clinical Study to Evaluate the Safety and Efficacy of SYS6010 in combination with Enlonstobart and Simmitinib in patients with advanced esophageal cancer
NCT06577376 / Not yet recruitingPhase 1/2
A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Simmitinib or Irinotecan Liposomes Combined With DP303c Injection in the Treatment of HER2 Expressing Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
100 Clinical Results associated with Simmitinib
Login to view more data
100 Translational Medicine associated with Simmitinib
Login to view more data
100 Patents (Medical) associated with Simmitinib
Login to view more data
1
Literatures (Medical) associated with Simmitinib
01 May 2022Bioanalysis
Development and Validation of a High Performance Liquid Chromatography–MS/MS Method for Determination of SOMCL-15-290 in a First-in-Human Study
100 Deals associated with Simmitinib
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Esophageal Squamous Cell CarcinomaPhase 3-
Shanghai Runshi Pharmaceutical Technology Co., Ltd.
31 Oct 2024
Esophageal Squamous Cell CarcinomaPhase 3
CN
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
13 Sep 2024
HER2-expressing Gastroesophageal Junction AdenocarcinomaPhase 2
CN
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
14 Sep 2024
HER2-expressing Gastroesophageal Junction AdenocarcinomaPhase 2
CN
Shanghai Runshi Pharmaceutical Technology Co., Ltd.
14 Sep 2024
HER2-expressing Gastric AdenocarcinomaPhase 2-
Shanghai Runshi Pharmaceutical Technology Co., Ltd.
26 Aug 2024
Metastatic Gastroesophageal Junction AdenocarcinomaPhase 2-
Shanghai Runshi Pharmaceutical Technology Co., Ltd.
26 Aug 2024
HER2-Low Breast CarcinomaPhase 2
CN
Shanghai Runshi Pharmaceutical Technology Co., Ltd.
22 Aug 2024
HER2-Low Breast CarcinomaPhase 2
CN
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
22 Aug 2024
HR-positive/HER2-low Solid TumorsPhase 2
CN
Shanghai Runshi Pharmaceutical Technology Co., Ltd.
30 Jan 2024
Advanced Malignant Solid NeoplasmPhase 2
CN
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
07 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04058587 (ASCO2024)
ManualManual
Phase 1
Advanced Malignant Solid Neoplasm
FGF3 | FGF4 | FGF19
98
Simmitinib 4 mg QD
ubdrkgcwmd(tozpmfhnlf) = MTD was not achieved pssecjtkya (zncfsefgzw )
View more
Positive
24 May 2024
Simmitinib 6 mg QD
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free